TScan Therapeutics (TCRX) Other Non Operating Income (2022 - 2026)

TScan Therapeutics (TCRX) has 5 years of Other Non Operating Income data on file, last reported at $473000.0 in Q1 2026.

• On a quarterly basis, Other Non Operating Income fell 77.72% year-over-year to $473000.0 in Q1 2026; TTM through Mar 2026 was $4.4 million, a 46.47% decrease from a year earlier, with the FY2025 full-year figure at $6.0 million, down 17.41% from the prior year.
• Other Non Operating Income for Q1 2026 stood at $473000.0, down from $881000.0 in the prior quarter.
• Over the last five years, Other Non Operating Income for TCRX reached as high as $2.7 million in Q3 2024 and fell as low as -$74000.0 in Q4 2022.
• Historically, Other Non Operating Income has averaged $1.1 million across 5 years, with a median of $903000.0 in 2024.
• Across the five-year window, Other Non Operating Income soared 2471.43% in 2023 and slumped 77.72% in 2026, its largest moves.
• Year by year, Other Non Operating Income stood at -$74000.0 in 2022, then jumped by 2456.76% to $1.7 million in 2023, then tumbled by 48.22% to $903000.0 in 2024, then retreated by 2.44% to $881000.0 in 2025, then sank by 46.31% to $473000.0 in 2026.
• Per Business Quant data, the three most recent Other Non Operating Income figures were $473000.0 in Q1 2026, $881000.0 in Q4 2025, and $1.3 million in Q3 2025.